Growth Hormone Resistance of Beta-cells A (NCT06571487) | Clinical Trial Compass
RecruitingNot Applicable
Growth Hormone Resistance of Beta-cells A
United States30 participantsStarted 2025-10-22
Plain-language summary
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.
Who can participate
Age range18 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Singleton, full term pregnancy within the past 5 years
* Body mass index ≥18.5 kg/m2 and \<45.0 kg/m2
Group specific inclusion criteria:
* Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy
* Control Group: no history of gestational diabetes
Exclusion Criteria:
* Pregnant, planning to become pregnant during the study, or breastfeeding
* Current diagnosis or history of type 1 or type 2 diabetes
* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
* History of bariatric surgery
* Known, uncontrolled hypothyroidism
* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
* Current cancer or cancer that has been in remission less than 5 years
* First degree relative with diabetes diagnosis
* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
* Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day
* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
What they're measuring
1
Beta-cell function
Timeframe: before and 7 days after rhGH administration